These data suggest that treatment with the two OX40 antibodies may cause different levels of decrease on CD4+ T cells and increase on CD8+ T cells in tumor (Figures 5A), yet they cause a similar level of IFN-γ expression, implicating T cell activation, on CD4+ and CD8+ cells, in tumor. The gene discussed is TNFRSF4; the disease is neoplasm.